anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The association between gastro-esophageal reflux disease (GERD) and cancer of the esophagus is well-established. Barrett's esophagus (BE) is a condition in which the lining of the part of the esophagus changes to look like small intestine, and this change occurs in the setting of GERD. Patients with BE are at increased risk for developing esophageal cancer. It is recommended that all patients with BE take medicines called proton pump inhibitors (PPIs), which greatly reduce the acid produced by the stomach, in the hopes of reducing the risk of esophageal cancer. However, by reducing the acid level in the stomach, levels of a hormone called gastrin are increased. There is laboratory data to suggest that gastrin may have effects that actually promote the development of cancer, including esophageal cancer. The investigators previously showed that BE patients with very high gastrin levels are more likely to have either advanced precancerous changes (also called high grade dysplasia) or cancer of the esophagus. As such, the obvious question is raised: does gastrin promote the development of cancer in BE? YF476 is a new drug that blocks the effects of gastrin. Trials in healthy subjects have demonstrated that the drug is safe and well-tolerated. The investigators therefore propose to conduct a randomized placebo-controlled trial of YF476 in patients with Barrett's esophagus. The primary hypothesis is that treatment with YF476 will reduce the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including monoclonal antibodies, bispecific T-cell engagers and chimeric antigen receptor T cells (CAR T cells), most MM patients now have a prolonged survival. However, the disease remains incurable, and a subgroup of high-risk patients continue to have early relapse and short survival. Novel and highly sensitive methods have been developed allowing the detection of minimal residual disease (MRD) during or after treatment. Achievement of MRD negativity is a strong and independent prognostic factor in both prospective randomized clinical trials and in the real-world setting. While MRD assessment is now a validated endpoint in clinical trials, its incorporation in clinical practice is not yet established and its potential impact on guiding therapy remains under in-depth evaluation. Here we discuss the different methods available for MRD assessment and the role of MRD evaluation in MM management.
Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased replication in malignant cells, thereby producing a cytopathic effect. The viral vectors of the invention may comprise additional genes of interest, and/or may have altered capsid proteins that may enhance infection of and/or target infection to cancer cells. Additional cell types derived from diseased states in which the PEG-3 promoter is selectively active are also therapeutic targets of the viral vectors of the instant invention including those generating allergic, autoimmune and inflammatory responses.
Despite evidence that both integral (i.e., related to the decision) and incidental (i.e., unrelated to the decision) emotions influence cancer-related decision making, no research has systematically examined whether these two types of emotion generate similar patterns of influence, as predicted by decision-making models. This is important because incidental emotions are often used experimentally to draw causal conclusions about how emotions influence cancer-related decisions with the notion that results will generalize to produce knowledge about integral emotions as well. Across three studies, we plan to directly compare integral and incidental emotional influences on judgments and decisions related to cancer control. We plan to examine whether effects are contingent on the type of emotional influence (the discrete emotions anger and fear, or general positive affect) or type of emotion induction (video, autobiographical induction, or evaluative conditioning). Across experiments, we predict that emotion will influence both judgment and decision-making outcomes when the induced emotion is integral as well as when it is incidental. However, we predict that the magnitude of the effect of emotion on these types of responses will be significantly greater when emotions are integral to a judgment or decision, compared to when emotions are incidental.
Examine the role, benefits, and limitations of robotic surgery in myomectomies compared to laparoscopic and open surgical approaches. This review sourced data from CENTRAL, Pubmed, Medline, and Embase up until May 1, 2023. Full articles comparing clinical outcomes of robotic myomectomy with open or laparoscopic procedures were included without language restriction. Initially, 2150 records were found. 24 studies were finally included for both qualitative and quantitative analyses. Two investigators independently assessed all reports following PRISMA guidelines. Meta-analysis was conducted using the software "Review Manager Version 5.4". Risk-of-bias was assessed using the Newcastle-Ottawa scale. Sensitivity analysis was conducted, when feasible. In a comparison between robotic and laparoscopic myomectomies, no significant difference was observed in fibroid weights and the size of the largest fibroid. Robotic myomectomy resulted in less blood loss, but transfusion rates were comparable. Both methods had similar complication rates and operative times, although some robotic studies showed longer durations. Conversion rates favored robotics. Hospital stays varied widely, with no overall significant difference, and pregnancy rates were similar between the two methods. When comparing robotic to open myomectomies, open procedures treated heavier and larger fibroids. They also had greater blood loss, but the robotic approach required fewer transfusions. The complication rate was slightly higher in open procedures. Open surgeries were generally faster, postoperative pain scores were similar, but hospital stays were longer for open procedures. Pregnancy rates were comparable for both robotic and open methods. Robotic surgery offers advancement in myomectomy procedures by offering enhanced exposure and dexterity, leading to reduced blood loss and improved patient outcomes. PROSPERO registration: CRD42023462348.
Asthma is the leading chronic childhood disease affecting 9 million children (12.5%) under 18 years of age (1). Asthma exacerbations cause an estimated 14 million missed school days (2) and more than 1.8 million emergency department (ED) visits annually (2), and account for \>60% of asthma-related costs (3). The chronic characteristic of asthma carries a considerable economic burden.

Uncontrolled asthma can lead to exacerbations requiring the patient to seek immediate care, frequently in an ED setting. Several asthma guidelines, including the nationally accepted guideline from the National Heart, Lung, and Blood Institute (NHLBI), exist to support clinicians in providing adequate treatment. Utilization of and adherence with asthma guidelines improves patients' clinical care (4, 5). However, guideline adherence remains suboptimal. In the ED, early recognition and accurate assessment of the severity of airway obstruction and response to therapy are fundamental to the improvement of health for patients with asthma. The NHLBI guidelines emphasize early recognition and treatment of asthma exacerbations, as well as appropriate treatment stratified by severity.

Computer applications for patient care can address barriers to optimal medical care. Computer systems have improved the use and adherence to practice guidelines, provide clinical alerts and reminders, and generate patient-specific treatment recommendations and educational material. Implementation of guideline-driven decision support is frequently paper-based or computerized. In either form a major barrier remains on the busy clinicians to remember to initiate the guideline a process and to embed the guideline tasks in the clinical workflow of the care team (5). The proposed study examines the benefits of a novel approach for reminding clinicians in an ED setting to use guideline-driven care. The approach will apply a workflow-embedded process taking advantage of an advanced information technology infrastructure. The informatics approach will include two elements: a) a computerized, real-time reminder system, which will automatically detect guideline-eligible patients without requiring additional data entry, and b) a computerized, workflow-embedded guideline implementation.
This invention is a method for producing a lip gloss(balm) with natural colorings. The lip gloss(balm) is made of lycopene extracted with cold-pressed olive oil, aromatic extract made by soaking in cold-pressed olive oil, beeswax, vegetable shortening, Radix Arnebiae wax-extract, and oil-extract. Wheatgerm oil is added according to need. First, Radix Arnebiae wax-extract made by blending beeswax and vegetable shortening is heated to approximately 75 DEG C so that it melts completed. The lycopene extracted with cold-pressed olive oil, Radix Arnebiae oil-extract and aromatic extract made by soaking in cold-pressed olive oil, preheated to a temperature of approximately 60 DEG C, is then blended in. A coloring and a herbal essential oil can be added to the lycopene extracted with cold-pressed olive oil, Radix Arnebiae oil-extract, and Radix Arnebiae wax-extract in certain propotions according to need. The mixture is placed in containers to cool, and then packaged.
Separating storage of personal from non-personal health information. At a server device, receiving and responding to requests from an application that involve access to both personal and non-personal health information. Parsing those requests into first portions which do not involve access to personal health information, and second portions which do. Referring those portions which involve access to personal health information to an information agent, which uses configuration information to determine how to access that personal health information. Separately accessing the personal health information using a secure key and referring an answer to those portions which involve access to both personal health information to the server device. At the server device, composing a response to requests from the application, including responses to both those first portions and those second portions.
Probucol is a cholesterol-lowering drug that has been removed from the market in Canada and the US, but remains in clinical use in Asia. In rodents, probucol increases synthesis and availability of apolipoprotein E (apoE) in the cerebrospinal fluid (CSF). ApoE is the protein product of the polymorphic gene APOE, allelic variation in which remains the strongest known risk factor (other than age itself) for Alzheimer's dementia. Oral Probucol is absorbed variably. Administration of a single, fixed dose therefore results in a wide range of plasma concentrations when the drug is given to various individuals in a fixed dosage. Limited human data suggest that higher plasma and CSF concentrations of probucol result in stronger increases in CSF apoE concentration. The dual aims of DEPEND are therefore 1) to develop an individualized dosing regimen that will result in plasma concentrations that are likely to increase CSF apoE concentration by 50%; and 2) to treat 20 persons at elevated risk of Alzheimer's dementia, each at his/her ideal individual dosage, for 12 months, observing the resulting change in CSF concentrations of apoE. Simultaneously, subjects will be observed carefully for evidence of any treatment effects on cognition or other probable markers of progression in pre-clinical Alzheimer's disease, as well as safety risks that might deter further human experimentation with the drug.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: group of inventions relates to medicine. The method consists in the fact that a composition containing a glucose antimetabolite is administered in a mammal. The specified composition contains an amount of the glucose antimetabolite sufficient to decrease a blood C-reactive protein level in the mammal after the introduction of the glucose antimetabolite. The glucose antimetabolite is selected from a group consisting of 2-deoxy-D-glucose, 5-thio-D-glucose, 3-O-methylglucose, anhydro sugar, 1,5-anhydro-D-glucitol, 2,5-anhydro-D-mannitol, mannoheptulose and their combinations. To decrease the blood C-reactive protein level in the mammal, such glucose antimetabolite as avocado, mannoheptulose and avocado extract are also used. ^ EFFECT: group of inventions allows effective inflammation and stress reduction in the mammal. ^ 38 cl, 144 ex
BACKGROUND: Substance use disorder in the United States represents a complex and growing public health crisis, marked by increasing rates of overdose deaths and the misuse of prescription medications. There is a critical need for furthering the understanding of the molecular and genetic mechanisms that can lead to substance use disorder. Identifying significant variants in the kynurenine pathway could help identify therapeutic targets for intervention.
METHODS: The All of Us cohort builder evaluated the frequency of variants of four genes, TDO2, IDO1, IDO2, and KMO, encoding enzymes in the kynurenine pathway. The samples were broken into six cohorts: alcohol, cannabis, cocaine, opioid, other use disorder, and control. Using Chi-square analysis, the frequency of at least one copy of a variant allele was calculated.
RESULTS: Chi-square analysis showed a significant variation in genetic frequency (p-value < 0.005) in 14 of 18 polymorphisms analyzed. The cocaine cohort had the most significant variants (13), cannabis had 11, opioids had 3, other use disorders had 2, and alcohol had 1 significant variant.
CONCLUSIONS: This study found associations of polymorphisms in the TDO2, IDO1, IDO2, and KMO genes of individuals with a substance use disorder. These results provide evidence of potential predictors of increased susceptibility to substance use disorder.
The present invention relates to a medicine having an excellent antifeeding activity, which contains, as the active componet, a substituted urea derivative or the pharmaceutically acceptable salt thereof.bThe present invention provides an antifeeding agent and / or anorectic agent, which contains, as the active componet, a substituted urea derivative of the following formula (I), [wherein, R1 represents a C6-10 aryl group optionally substituted with 1-5 groups selected from substituents a etc.; R2 represents a C6-10 aryl group optionally substituted with 1-5 groups selected from substituents a etc.; E represents a group of the formula (II) or (III) (wherein, R3 represents a hydrogen atom etc.; R4 and R5 may be the same or different, each represents a hydrogen atom etc.; X and U may be the same or different, each represents a group of the formula CH etc.; m and n may be the same or different, each represents 1 etc.) ; A represents a group of the formula -NH-C(=O)- etc.], or the pharmaceutically acceptable salt thereof.
PURPOSE: A composition for treating breast cancer which contains ant2 siRNA or ant2 shRNA is provided to enhance breast cancer treating effect of TRAIL. CONSTITUTION: A composition for treating breast cancer which contains adenine nucleotide translocator 2 small interfering RNA(ANT2 siRNA) or ANT2 short hairpin RNA(shRNA) as an active ingredient and suppresses transition of the breast cancer cells. The ANT2 siRNA or ANT2 shRNA induces decomposition of ANT2 mRNA by combining the anti-sense sequence described in the sequence number 3(SEQ ID NO:3) with the sequence number 1. The composition drops the expression of the HER2/neu(human epidermal growth factor receptor 2). The composition multiplies the treatment effects of the breast cancer the TRAIL(TNF-related apoptosis-inducing ligand). The composition multiplies the expression of DR 4(death receptor 4) and DR5(death receptor 5) on the breast cancer cell surface.
Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
Local anesthetics, including ropivacaine, rapidly cross the placenta, and when used for epidural block can cause varying degrees of maternal, fetal and neonatal toxicity (see CLINICAL PHARMACOLOGY and PHARMACOKINETICS). The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function. 

Maternal hypotension has resulted from regional anesthesia with Ropivacaine Hydrochloride for obstetrical pain relief. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient's legs and positioning her on her left side will help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable. Epidural anesthesia has been reported to prolong the second stage of labor by removing the patient's reflex urge to bear down or by interfering with motor function. Spontaneous vertex delivery occurred more frequently in patients receiving Ropivacaine Hydrochloride than in those receiving bupivacaine.
When pregnancy occurs in adolescence, the growth and development of the mother and fetus may be impaired due to strong competition for nutrients between the still-growing adolescent and the fetus. Pregnant adolescents constitute an underserved population; they lack adequate nutritional knowledge. Therefore, this study investigated the effect of nutritional behavior change communication (NBCC) through alliance for development (AFD) on the nutritional status and gestational weight gain (GWG) of pregnant adolescents. A two-arm parallel cluster randomized controlled community trial was conducted in the West Arsi Zone, central Ethiopia, from August 2022 to July 2023. The nutritional status of the pregnant adolescent was assessed using mid-upper arm circumference. Weight was measured at baseline and at the end of the intervention. A total of 207 and 219 pregnant adolescents participated in the intervention and control clusters, respectively. The intervention started before 16 weeks of gestation, and the intervention group attended four NBCC sessions. The NBCC was based on the health belief model (HBM) and was given at the participants' homes with their husbands. The NBCC intervention was delivered by AFDs and community-level health actors. Pregnant adolescents in the control group received routine nutrition education from the health care system. A linear mixed-effects model and difference in difference (DID) were used to measure the intervention effect after adjusting for potential confounders. After the implementation of the trial, the mean mid-upper arm circumference (MUAC) in the intervention arm significantly increased from baseline (p ≤ 0.001), 23.19 ± 2.1 to 25.06 ± 2.9 among intervention group and 23.49 ± 2.1 to 23.56 ± 2.0 among control group and the mean difference in the MUAC (DID) was 1.89 ± 2 cm (p ≤ 0.001); the mean GWG in the intervention arm significantly increased from baseline; 51.54 ± 4.7 to 60.98 ± 4.6 among intervention group and 52.86 ± 5.27 to 58 ± 5.3 among control group; the mean GWG in the intervention group was 9.4 kg, and that in the control group was 5.14 kg, and the difference in difference was 4.23 kg and this was statically significant p ≤ 0.001). This study demonstrated that the use of the HBM for NBCC delivered through the AFD was effective at improving the nutritional status and GWG of pregnant adolescents. These results imply the need for the design of model-based nutritional counseling guidelines.Clinical trial registration: PACTR202203696996305, Pan African Clinical Trials Registry, date of first registration: 16/03/2022.
PURPOSE: A cosmetic composition containing Astilbe chinensis var. davidii extract for improving anti-wrinkling is provided to promote skin cell proliferation and to ensure antioxidation. CONSTITUTION: A cosmetic composition for improving anti-wrinkling contains 0.0001-10 weight% of Astilbe chinensis var. davidii extract as an active ingredient, prepared by supercritical fluid extraction. The supercritical fluid extraction is performed together with at 35-100°C and at the pressure of 100-500 using ethanol, methanol, water, ethyl acetate, hexane, or diethyl ether. The composition is manufactured in the form of a solution, suspension, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, or spray.
PROBLEM TO BE SOLVED: To provide an agent containing a nacreous pigment of full interest at the time of use. SOLUTION: This agent containing a surfactant, a nacreous pigment and a redispersing agent in order to facilitate the redispersion of the nacreous pigment in the agent containing the nacreous pigment is filled together with a gas propellant in an aerosol container to thereby enable the discharge thereof in a foamy state without producing a pearly luster. Thereby, the pearly luster can be produced after defoaming. As a result, the agent can be made to stick to hair of the head in a state without production of the pearly luster in the case of the use as, e.g. a hair dye. Foams can be collapsed and eliminated with the passage of time to provide the pearly luster from the hair of head. Thereby, the agent can be made to stir up a great interest in users, etc., at the time of use.
PURPOSE: To describe a case report of a 34 years-old patient with Crohn's Disease and two episodes of Ocular Myositis.
METHODS: The research methodology employed in this study consisted of a retrospective review of the patient's complete medical history.
RESULTS: Crohn's Disease is a chronic inflammatory bowel disorder known to be associated with a wide range of extraintestinal manifestations. Ocular abnormalities, such as episcleritis and uveitis, are commonly observed. However, orbital myositis is an extremely rare ocular extraintestinal manifestations characterized by acute ocular pain that worsens with eye movements and is often accompanied by diplopia. In this case report, we present the case of a 34-year-old woman with a confirmed diagnosis of Crohn's Disease, who experienced two episodes of acute orbital pain exacerbated by ocular movements and diplopia. The diagnosis was established through clinical evaluation and radiologic imaging, with confirmation after a good response to systemic corticosteroids. She responded favorably to systemic corticosteroid therapy on both episodes, and no additional treatment was required. As of now, she remains stable without any ocular sequelae.
CONCLUSION: It is important to note that orbital myositis is an uncommon ocular manifestation associated with Crohn's Disease, and prompt recognition and management are crucial to achieve successful outcomes.